A Resistência Antimicrobiana E Custos De Cuidado De Saúde: Uma Revisão Sistemática

Abstract

There is a growing concern about the multi-resistant capabilities presented by microorganisms to antimicrobials. Society is harmed by the redirection of financial resources from other areas, also lacking the population, to purchase more potent antimicrobials and in larger quantities. This study describes the consumption of antimicrobial drugs and their impact generated through a systematic review, following the recommendations of the Prisma method. Searches were performed in four databases (Portal BVS, PubMed, Embase and Science Direct). A total of 196 articles were found, 11 of which were selected after applying the eligibility criteria. A prospective study showed that the difference in expenditures can reach $31.17 patients/day between prophylactics and those with nosocomial infections. Studies have shown that the increase in costs is related to the increase in the length of stay. Mortality and admission to the ICU also increased. Further studies with high levels of evidence are recommended.

Delineamento de infecções em um hospital universitário por bactérias produtoras de metalobetalactamases: mapeando o inimigo!

“…Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde pISSN: 2179-5924 Metallo-Beta-Lactamases (MBLs) are enzymes that confer bacteria the ability to resist the action of practically all known antimicrobials (ATMs) 1 . As they are difficult to treat, infections caused by bacteria that produce MBLs increase hospitalization time and morbidity/mortality in hospitals 2 and increase the costs of health systems 3 . The World Health Organization (WHO) identifies antimicrobial resistance as one of the biggest threats to global Public Health.…”

Atenção farmacêutica na dispensação de antimicrobianos, em farmácias comunitárias e drogarias, no combate a Resistência Antimicrobiana

“…Vale lembrar, que tomadas de decisões que constitui para um uso racional e seguro dos antimicrobianos, há necessidade de atuação de todas as esferas governamentais para combater a RAM. Um estudo realizado pelo economista britânico Jim O'Neill aponta que anualmente mais de 700 mil pessoas vão a óbito devido à resistência antimicrobiana e caso este cenário não sofra alterações, até 2050 a RAM se tornará mais letal que o câncer, podendo atingir a marca de 10 milhões de mortes por ano (Silva & Ortega, 2021).…”